Gathua S N, Aluoch J A
Infectious Disease Hospital, Nairobi, Kenya.
East Afr Med J. 1990 Dec;67(12):850-5.
The treatment of asthma in Africa is influenced by cultural and environmental factors as well as the availability of drugs. Poor compliance with regard to long-term maintenance treatment of chronic asthma is also a problem in Africa. The present study reports on 45 patients from 2 centres in Nairobi treated with 8 mg twice daily of an oral controlled release formulation of salbutamol ("Volmax"). The treatment produced a significant improvement in lung function measured by the PEFR compared with baseline data on previous therapy. Controlled release salbutamol was rated as effective or very effective by 84.2% of patients and for 81.6% of patients their physicians preferred this preparation to the therapy used before the study. Side effects were infrequent and usually occurred during the first few days of treatment. The study which is the first report in Africa to assess this novel formulation of salbutamol in a group of African patients, demonstrates that controlled release salbutamol 8 mg administered twice daily is safe and effective, offering benefits over current therapies in the treatment of asthma.
非洲哮喘的治疗受到文化、环境因素以及药物可及性的影响。在非洲，慢性哮喘长期维持治疗的依从性差也是一个问题。本研究报告了内罗毕两个中心的45例患者，他们接受了每日两次、每次8毫克的口服控释沙丁胺醇制剂（“喘乐宁”）治疗。与先前治疗的基线数据相比，该治疗使通过呼气峰流速（PEFR）测量的肺功能有显著改善。84.2%的患者将控释沙丁胺醇评为有效或非常有效，81.6%患者的医生表示相较于研究前使用的治疗方法，他们更倾向于这种制剂。副作用很少见，通常发生在治疗的头几天。这项研究是非洲首次在一组非洲患者中评估这种新型沙丁胺醇制剂的报告，表明每日两次服用8毫克控释沙丁胺醇是安全有效的，在哮喘治疗中比现有疗法更具优势。
